retreatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis c who have relapsed or not responded to a first course of pegylated interferon-based therapy

retreatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis c who have relapsed or not responded to a first course of pegylated interferon-based therapy

;Eric M Yoshida;Morris Sherman;Vincent G Bain;Curtis L Cooper;Marc Deschênes;Paul J Marotta;Samuel S Lee;Mel Krajden;Helga Witt-Sullivan;Robert J Bailey;Christopher Usaty;Kevork Peltekian;the Canadian Pegasys Study Group
indian journal of pharmacology 2009 Vol. 23 pp. 180-184
212
yoshida2009canadianretreatment

Abstract

BACKGROUND: Pegylated interferon (pegIFN) and ribavirin combination therapy remains the first-line treatment for chronic hepatitis C virus (HCV) infection. In contrast to the wealth of studies in treatment-naive patients, the effectiveness of retreatment in patients who have previously failed pegIFN-based therapy is largely unreported.

Citation

ID: 210278
Ref Key: yoshida2009canadianretreatment
Use this key to autocite in SciMatic or Thesis Manager

References

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
210278
Unique Identifier:
10.1155/2009/470532
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet

Saymatik Web3.0 Wallet